0R55 Stock Overview
BioSenic S.A., a biotech company, focuses on developing clinical assets.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BioSenic S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.015 |
| 52 Week High | €0.19 |
| 52 Week Low | €0.015 |
| Beta | 0 |
| 1 Month Change | -28.50% |
| 3 Month Change | -61.75% |
| 1 Year Change | -84.70% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R55 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -23.5% | 0.5% | 2.7% |
| 1Y | -84.7% | -29.8% | 0.3% |
Return vs Industry: 0R55 underperformed the UK Biotechs industry which returned -29.8% over the past year.
Return vs Market: 0R55 underperformed the UK Market which returned 0.3% over the past year.
Price Volatility
| 0R55 volatility | |
|---|---|
| 0R55 Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0R55's share price has been volatile over the past 3 months.
Volatility Over Time: 0R55's weekly volatility has decreased from 24% to 15% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | François Rieger | www.biosenic.com |
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures’ and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment.
BioSenic S.A. Fundamentals Summary
| 0R55 fundamental statistics | |
|---|---|
| Market cap | €2.94m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 0R55 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R55 income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
Jun 06, 2024
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 0R55 perform over the long term?
See historical performance and comparison